QUICK ANSWER · AEO / GEO
Ramatercept is an ActRIIB-IgG1 Fc ligand trap, not follistatin. Short human trials found body-composition signals but did not establish functional benefit; the DMD Phase 2 study stopped on safety concerns including epistaxis and telangiectasias. Unverified online products cannot inherit clinical-trial evidence.
ENTITY FACTS
What should readers identify first?
EVIDENCE BOUNDARY
What this overview does not establish
- An evidence grade does not rank this molecule against another treatment.
- A molecule name does not establish the identity, purity or regulatory status of a product.
- Animal, cell or biomarker findings do not automatically establish human clinical benefit.
- Approval in one country or indication does not transfer globally.
FAQ · ANSWER ENGINE
Frequently asked questions
What is ACE-031?
ACE-031 is described pharmacologically as Soluble activin receptor type IIB–IgG1 Fc fusion protein and broad ligand trap. Ramatercept is an ActRIIB-IgG1 Fc ligand trap, not follistatin. Short human trials found body-composition signals but did not establish functional benefit; the DMD Phase 2 study stopped on safety concerns including epistaxis and telangiectasias. Unverified online products cannot inherit clinical-trial evidence.
Does ACE-031 have strong evidence?
PrimeCoreBio records Evidence Grade B. This grade describes evidence strength, not comparative effectiveness or suitability for an individual.
Is ACE-031 approved everywhere?
No global conclusion should be inferred. PrimeCore Class B must be read with the exact product, country and indication on the source-rich profile.
Educational information only. This page does not provide diagnosis, treatment, prescribing, dosage, injection instructions or individual medical advice.